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Substance Addiction as Societal Phenomenon—the Case of
Serbia
Psychoactive substance addiction presents a challenging public health issue worldwide particularly
targeting vulnerable adolescent population (Babor et al., 2007). The illegal market turnover of the
controlled substances is very difficult to trace and intervene timely among the young in the early
stage of illness (Inciardi et al., 2007). Contrary to this one, legally regulated pharmaceuticals pose
another dangerous threat that is more accessible to the authorities. In order to combat substance
dependence the national strategies should specially emphasize prescription medicines with proven
potential of abuse and addiction (Compton and Volkow, 2006).
Serbia as the largest Western Balkans market and a typical Eastern European transitional
health system might serve as an appropriate example of medicines abuse in the EU borderlands
(Jakovljevic, 2013). The results of local research in 2008, showed that 15.1% of first grade high
school students, at least once had used, some psychoactive substance (excluding nicotine and
alcohol), while 7.6% of them used sedatives, which was the most common [European School Survey
Project on Alcohol and Other Drugs (ESSPAD), 2008]. The national survey on life styles of citizens
in Serbia in 2014 about substance use and gambling addiction reported that in the past 12 months
22.4% of the respondents used sedatives, anxiolytics or hypnotics drugs (13.9% of males and 30.9%
of females) and in the last 30 days 14.6% of respondents (8% of males and 21.2% of females) used
these drugs with higher preponderance among older population. In the last 12 months 5.1% of
the respondents used opioids for pain treatment (4.1% of males and 6.1% of females) and in the
last 30 days 2.2% of respondents (1.6% of males and 2.8% of females) used these drugs. A large
number of respondents said that they had purchased these drugs in the pharmacies prescribed by
their physicians –85.3% of the population 18–64 years of age used hypnotics and sedatives, and
70.3% of the population used opioid drugs (Kilibarda et al., 2014).
Various studies have shown that drug addiction disorders are related to personality disorders,
anxiety disorders and a considerably higher suicide rate (Regier et al., 1990). Further consequences
of drug addiction are: education (Yamada et al., 1993) and employment underachievement, reduced
work productivity, poor health, higher rates of human immunodeficiency virus (HIV) and hepatitis
B and C infections (Jakovljevic et al., 2013a), social dysfunction, higher rate of violence and
incarceration among that population, poverty, homelessness, a lower probability of recovery, poor
treatment outcomes, and poor quality of life. The treatment system for substance use disorders is
accompanied by high public and private expenses (Jovanovic and Jakovljevic, 2011).
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Pharmaceutical Market in a Late-stage
Transitional Health Reform Setting
The national health care system of Serbia is financed by
mandatory tax contributions by employers and employees
alike to the National Health Insurance Fund. The health care
system of Serbia similar to Eastern European countries, have
undergone profound transitional reforms with different degrees
of success in different areas of medical service provision and
outcomes (Jakovljevic et al., 2011). Over the last 20 years,
pharmaceutical and total health care expenditures were growing
more rapidly than gross domestic product (GDP) in many world
regions (Getzen, 1990). The Serbian pharmaceutical market
was characterized by a large growth in public expenditure on
pharmaceuticals (from e339,279,304 in 2004 to e794,560,045 in
2013). The Sudden expansion in the market led to the increase
of Serbia’s public debt and accumulated debt of wholesalers
toward brand industry in the entire region (Jakovljevic et al.,
2015a). These developments eventually led to the crisis of
financial sustainability and serious market shortages of even
some fundamental medicines (Jakovljevic, 2014). Primary health
care facilities were intended to act as “gate keepers” of the
health care system. Their success in this role to contain “supplier
induced demand” in clinical medicine was frequently examined
in public opinion (Vukovic´ et al., 2015). Preventive public health
measures and early screening procedures remain an ongoing
weakness of the most regional health systems and Serbia is no
exception. In the long run, the evolution of prosperity diseases
and accelerated population aging are most likely to persist as the
core challenges in the broader Balkans region (Jakovljevic and
Laaser, 2015).
Signs of Addictive Prescription Medicines
Abuse
Published trials from late 1990s provide clear-cut evidence
of upward trend in the consumption of psychiatric drugs
in Serbia and Montenegro (Miljkovic and Djukic, 2000).
The Utilization of all drugs acting on the nervous system
(inclusive of psychiatric drugs) grew from 28.9 DDD/1000
inhabitants/day in 1996 to 69.1 DDD/1000 inhabitants/day in
2004. Among the causes of this growth, the most frequently
cited are increased incidence of psychiatric disorders, post-war
syndromes that followed the Yugoslav civil wars and higher
accessibility of prescription medicines at the time (Divac et al.,
2004).
Contemporary policy, since the early 2000s, is that majority
of approved and marketed potentially addictive medicines
are assigned to the positive list and completely reimbursed
within the basic health insurance premium. Extensive annual
reports on prescription and dispensing of drugs in terms of
defined daily doses per 1000 inhabitants per day (DDD/1000
inhabitants/day) are released at regular times by the National
Medicines and Medicinal Devices Agency of Serbia (ALIMS;
Agencija za lekove i medicinska sredstva Srbije, 2013). In Table 1
we can remark DDDs and value base turnover of six selected
ATC (Anatomical Therapeutic Chemical Classification System)1
code groups of such medicines: anesthetics, opioids, anxiolytics,
hypnotics and sedatives, psychostimulants, agents used for
ADHD (Attention deficit hyperactivity disorder), nootropics and
drugs used in addictive disorders. The results are presented
using WHO recommended ATC/DDD methodology (Sjöqvist
and Birkett, 2003). The consumption of psychostimulants, agents
used for ADHD and nootropics grew tremendously (from
0.35 DDD/1000 inhabitants/day in 2004 to 6.61 DDD/1000
inhabitants/day in 2013). The consumption of hypnotics
and sedatives has almost doubled (from 2.47 DDD/1000
inhabitants/day in 2004 to 4.02 DDD/10000 inhabitants/day in
2013) primarily due to benzodiazepine derivatives. A promising
sign is the rise of prescription of drugs used to treat addictive
disorders (from 0.31 DDD/1000 inhabitants/day in 2004 to 1.50
DDD/1000 inhabitants/day in 2013). Among these ATC code
groups, the most frequent consumption was recorded in the case
of agents that are indicated in opioid dependence.
Pharmaceutical spending related to all of the aforementioned
groups of medicines has strongly increased during the same time
span. The most significant budget impact was attributed to the
anxiolytics consumption in 2013 (e15,091,052) in comparison
to e9,450,094 back in 2004. This finding is wholly justified
by previous findings on heavily increased anxiety levels among
resident addicts in the former Yugoslav region compared
to traditional EU-15 market economies (Jakovljevic et al.,
2013b). Psychostimulants related costs were multiplied 10-fold
(e287,766 in 2004 to e3,138,433 in 2013). Over the same time
horizon following aforementioned growth pattern inDDD terms,
the costs of pharmaceuticals used to treat substance dependence
increased heavily as well (from e236,734 in 2004 to e1,900,777
in 2013).
Conclusive Remarks
Although the situation appears to implicate an extensive public
debate in this region, we should be aware of the fact that
a large portion of reported consumption is clinically justified
with basic mental illness. It would be highly difficult and
demanding rigorous methodological approach to exactly identify
the proportion of overutilization of these drugs that is attributed
to abuse and addiction. Nevertheless, vast net quantity gains in
consumed addictive medications in definite ATC groups by far
surpass extended burden of associated psychiatric morbidity in
recent years (Ristic-Ignjatovic et al., 2013). Therefore, this insight
gives grounds for serious concerns about widespread patient
abuse of addictive medicines in this country and beyond.
The abuse of potentially addictive medicines correlates with
clinicians’ decision making principles (Bendtsen et al., 1999)
and locally prevailing psychiatrist practice (Jakovljevic et al.,
2015b). Citizens’ possibility to purchase these medicines without
medical prescription has been proven as another major driver
of abuse potential (Lessenger and Feinberg, 2008). It is reported
that up to 4.4% adults consuming sedatives and hypnotics
1Anatomical Therapeutic Chemical Classification System. Available online at:
http://www.whocc.no/atc_ddd_index/.
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TABLE 1 | National level dispensing (Defined Daily Doses per 1000 population/day) and consumption (e) of major potentially addictive medicines and
those used to treat substance addiction in 2004 and 2013 in Serbia.
ATC code group Reimbursed value
of dispensed
medicines in 2004
Reimbursed value
of dispensed
medicines in 2013
DDD per 1000
inhabitants/hospital
day in 2004
DDD per 1000
inhabitants/hospital
day in 2013
POTENTIALLY ADDICTIVE MEDICINES
N01A Anesthetics, General e1,283,128 e4,072,544 N/A N/A
N01AF Barbiturates, plain e21,465 e101,8422009 N/A N/A
N02A Opioids e1,472,459 e2,499,864 0.84 0.52
N02AA Natural opium alkaloids e197,341 e611,410 0.04 0.08
N02AB Phenylpiperidine derivatives e272,205 e1,341,574 0.03 0.11
N02AD Benzomorphan derivatives e818 e5062006 0.00 N/A
N02AX Other opioids (mostly tramadol based preparations) e1,002,095 e546,880 0.77 0.33
N03AA Barbiturates and derivatives e427,676 e263,570 2.9 2.03
N03AE Benzodiazepine derivatives e291,568 e1,288,405 0.63 2.48
N05AH Diazepines, oxazepines, thiazepines, and oxepines e1,529,558 e4,925,668 0.37 1.53
N05B Anxiolytics e9,450,094 e15,091,052 106.95 79.81
N05BA Benzodiazepine derivatives e9,448,412 e15,091,052 106.95 79.81
N05C Hypnotics and sedatives e1,197,390 e2,232,897 2.47 4.02
N05CD Benzodiazepine derivatives e1,197,390 e1,459,522 2.47 1.98
N05CF Benzodiazepine related drugs e0 e773,375 0.00 2.03
N06B Psychostimulants, agents used for ADHD and nootropics e287,766 e3,138,433 0.35 6.61
R01AA Sympathomimetics, plain (mostly ephedrine based preparations) e1,676,145 e4,328,551 132.14 14.83
R05DA Opium alkaloids and derivatives e74,118 e28,649 0.05 0.03
R06AB Substituted alkylamines (mostly pheniramine derivatives) e492,461 e2,764,304 0.56 0.08
MEDICINES USED TO TREAT SUBSTANCE ADDICTION
N07B Drugs used in addictive disorders e236,734 e1,900,777 0.31 1.50
N07BA Drugs used in nicotine dependence e138,139 e407,718 0.03 0.10
N07BB Drugs used in alcohol dependence e35,123 e206,726 0.19 0.53
N07BC Drugs used in opioid dependence e63,472 e1,286,332 0.09 0.88
on a daily base. This amounts to an overall population of
182,000–234,000 regular users of sedatives and hypnotics among
population aged from 18 to 64. This phenomena might have
a difficult and concerning extent among the small Balkan
nations (Divac et al., 2009). Similar life styles reported in
public health surveys across EU might indicate that the
abuse of potentially addictive medicines could have the far
reaching consequences in the European continent (United
Nations Office on Drugs and Crime, 2010). There are several
possible tactics to cope with this challenge for overprescribing
pattern and irrational consumption of these medicines could
be partially controlled by paying more attention to potentially
susceptible patients during regular check-ups (Khan et al.,
2015). Strengthening of the regulatory framework in marketing
approval and reimbursement could impose more strict legal
control to the over-the-counter sales of this medicines. Software
based good clinical practice guidelines have already confirmed
strong benefits in terms of patient outcomes and cost savings
in a local clinical setting (Jakovljevic et al., 2014). Health
education program development targeted for addictive patients’
needs (Wolde et al., 2008) and those suffering from other
mental illnesses at the risk of developing substance dependence,
could improve patient support and counseling (Hashemi and
Hashemi, 2015). The experience of the successful implementation
of alternative and complementary medicine methods attained
in many countries, might serve as an additional example of
exit strategies probably to bring relief to this vulnerable patient
population.
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